HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome.

AbstractOBJECTIVE:
To evaluate the safety of liposomal PGE1 (TLC C-53) in patients with acute respiratory distress syndrome (ARDS), and determine its efficacy in improving oxygenation and reducing ventilator dependency.
DESIGN:
A multi-centre, randomized, double-blind, placebo-controlled clinical study.
SETTING:
Thirty-one hospitals in six European countries.
PATIENTS:
One hundred two patients with ARDS.
INTERVENTIONS:
Patients were randomized in a 2:1 ratio to receive infusions of either the study drug TLC C-53 or placebo. Infusions were given over 60 min every 6 h for 7 days. The dose of study drug started at 0.6 microg/kg per h, rising over 24 h to a maximum dose of 1.8 microg/kg per h.
MEASUREMENTS AND MAIN RESULTS:
Seventy patients received the study drug and 32 placebo. Sixty-nine patients (47 treatment, 22 placebo) completed the study protocol. Patients were monitored for changes in the PaO2/FIO2 ratio, changes in lung compliance, time to off-ventilator and 28-day mortality, in addition to basic haematological and haemodynamic parameters. There were no significant differences in demographics and baseline characteristics between the two groups. There were no differences in the time to off-ventilation (16 days with treatment, 16.6 days with placebo, p=0.94) or in 28-day mortality (30% with treatment, 28% with placebo, p=0.78). There was a difference in the time to achieve a PaO2/FIO2 ratio above 300 in favour of TLC C-53 (10.3 versus 26.5 days) but this was not statistically significant (p=0.23).
CONCLUSIONS:
TLC C-53 was generally well-tolerated but failed to reduce mortality or duration of mechanical ventilation.
AuthorsJ L Vincent, R Brase, F Santman, P M Suter, A McLuckie, J F Dhainaut, Y Park, J Karmel
JournalIntensive care medicine (Intensive Care Med) Vol. 27 Issue 10 Pg. 1578-83 (Oct 2001) ISSN: 0342-4642 [Print] United States
PMID11685297 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Liposomes
  • Vasodilator Agents
  • Alprostadil
Topics
  • Aged
  • Alprostadil (administration & dosage, immunology, pharmacology)
  • Blood Gas Analysis
  • Critical Care (methods)
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Monitoring
  • Female
  • Hemodynamics (drug effects)
  • Hospital Mortality
  • Humans
  • Infusions, Intravenous
  • Liposomes
  • Lung Compliance (drug effects)
  • Male
  • Middle Aged
  • Neutrophils (drug effects)
  • Proportional Hazards Models
  • Respiration, Artificial
  • Respiratory Distress Syndrome (drug therapy, immunology, metabolism, mortality, physiopathology)
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome
  • Vasodilator Agents (administration & dosage, immunology, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: